Betting on a malaria vaccine

New England Journal of Medicine

Volumn 353, Issue 18, 2005, Pages 1877-1881

  Okie, Susan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

DRUG EFFICACY; DRUG RESEARCH; FINANCIAL MANAGEMENT; HUMAN; MALARIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW;

ADULT; AFRICA; ANIMALS; CHILD, PRESCHOOL; CLINICAL TRIALS; HUMANS; INFANT; INTERNATIONAL COOPERATION; LIFE CYCLE STAGES; MALARIA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM;

EID: 27644474627     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp058217     Document Type: Review

References (5)

1. Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet 2005;365:1487-98.
2. Portfolio of candidate malaria vaccines currently in development: March 2005. (Accessed October 13, 2005, at http://who.int/vaccine_research/documents/ en/malaria_ table.pdf.)
3. Bojang KA, Milligan PJ, Pinder M, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. Lancet 2001;358:1927-34.
4. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004;364:1411-20.
5. Moorthy VS, Imoukhuede EB, Milligan P, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 2004;1(2):e33.